Thomas Grunt

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7133020/publications.pdf

Version: 2024-02-01

35 papers	5,234 citations	304368 22 h-index	377514 34 g-index
36 all docs	36 docs citations	36 times ranked	12994 citing authors

#	Article	IF	Citations
1	Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy, 2012, 8, 445-544.	4.3	3,122
2	Correlation of circular RNA abundance with proliferation â€“ exemplified with colorectal and ovarian cancer, idiopathic lung fibrosis and normal human tissues. Scientific Reports, 2015, 5, 8057.	1.6	653
3	c-erbB-3. Journal of Cell Biology, 2002, 157, 929-940.	2.3	193
4	Heterotypic CAF-tumor spheroids promote early peritoneal metastasis of ovarian cancer. Journal of Experimental Medicine, 2019, 216, 688-703.	4.2	145
5	Inhibition of the mevalonate pathway affects epigenetic regulation in cancer cells. Cancer Genetics, 2015, 208, 241-252.	0.2	84
6	Cancer stem cells in basic science and in translational oncology: can we translate into clinical application?. Journal of Hematology and Oncology, 2015, 8, 16.	6.9	80
7	Overexpression of G proteinâ€coupled receptor 5D in the bone marrow is associated with poor prognosis in patients with multiple myeloma. European Journal of Clinical Investigation, 2012, 42, 953-960.	1.7	79
8	Interaction between fatty acid synthase- and ErbB-systems in ovarian cancer cells. Biochemical and Biophysical Research Communications, 2009, 385, 454-459.	1.0	77
9	Novel Approaches for Molecular Targeted Therapy of Breast Cancer: Interfering with PI3K/AKT/mTOR Signaling. Current Cancer Drug Targets, 2013, 13, 188-204.	0.8	72
10	Bidirectional interactions between the estrogen receptor and the c-erbB-2 signaling pathways: Heregulin inhibits estrogenic effects in breast cancer cells. International Journal of Cancer, 1995, 63, 560-567.	2.3	71
11	Alternative Splicing of Fibroblast Growth Factor Receptor IgIII Loops in Cancer. Journal of Nucleic Acids, 2012, 2012, 1-12.	0.8	69
12	Blockade of Fatty Acid Synthase Induces Ubiquitination and Degradation of Phosphoinositide-3-Kinase Signaling Proteins in Ovarian Cancer. Molecular Cancer Research, 2011, 9, 1767-1779.	1.5	62
13	Fatty acid synthase is a metabolic marker of cell proliferation rather than malignancy in ovarian cancer and its precursor cells. International Journal of Cancer, 2015, 136, 2078-2090.	2.3	60
14	Interacting Cancer Machineries: Cell Signaling, Lipid Metabolism, and Epigenetics. Trends in Endocrinology and Metabolism, 2018, 29, 86-98.	3.1	59
15	Retinoic acid induced death of ovarian carcinoma cells correlates with c-myc stimulation. International Journal of Cancer, 1995, 61, 649-657.	2.3	58
16	The PI3 kinase/mTOR blocker NVP-BEZ235 overrides resistance against irreversible ErbB inhibitors in breast cancer cells. Breast Cancer Research and Treatment, 2011, 129, 387-400.	1.1	52
17	Multi-level suppression of receptor-PI3K-mTORC1 by fatty acid synthase inhibitors is crucial for their efficacy against ovarian cancer cells. Oncotarget, 2017, 8, 11600-11613.	0.8	43
18	hVps37A Status Affects Prognosis and Cetuximab Sensitivity in Ovarian Cancer. Clinical Cancer Research, 2011, 17, 7816-7827.	3.2	37

#	Article	IF	Citations
19	Neoplastic stem cells: Current concepts and clinical perspectives. Critical Reviews in Oncology/Hematology, 2010, 76, 79-98.	2.0	29
20	The major vault protein mediates resistance to epidermal growth factor receptor inhibition in human hepatoma cells. Cancer Letters, 2012, 319, 164-172.	3.2	24
21	Differential expression of mTOR components in endometriosis and ovarian cancer: Effects of rapalogues and dual kinase inhibitors on mTORC1 and mTORC2 stoichiometry. International Journal of Molecular Medicine, 2019, 43, 47-56.	1.8	24
22	The role of c-FLIPL in ovarian cancer: Chaperoning tumor cells from immunosurveillance and increasing their invasive potential. Gynecologic Oncology, 2010, 117, 451-459.	0.6	23
23	Hitting two oncogenic machineries in cancer cells: cooperative effects of the multi-kinase inhibitor ponatinib and the BET bromodomain blockers JQ1 or dBET1 on human carcinoma cells. Oncotarget, 2018, 9, 26491-26506.	0.8	23
24	HER Specific TKIs Exert Their Antineoplastic Effects on Breast Cancer Cell Lines through the Involvement of STAT5 and JNK. PLoS ONE, 2016, 11, e0146311.	1.1	21
25	Comparative transcriptome analysis links distinct peritoneal tumor spread types, miliary and non-miliary, with putative origin, tubes and ovaries, in high grade serous ovarian cancer. Cancer Letters, 2017, 388, 158-166.	3.2	15
26	Membrane disruption, but not metabolic rewiring, is the key mechanism of anticancer-action of FASN-inhibitors: a multi-omics analysis in ovarian cancer. Scientific Reports, 2020, 10, 14877.	1.6	13
27	Upregulation of retinoic acid receptor-Î² by the epidermal growth factor-receptor inhibitor PD153035 is not mediated by blockade of ErbB pathways. Journal of Cellular Physiology, 2007, 211, 803-815.	2.0	12
28	Estradiol impairs the antiproliferative and proapoptotic effect of Zoledronic acid in hormone sensitive breast cancer cells in vitro. PLoS ONE, 2017, 12, e0185566.	1.1	7
29	In vitro and in vivo evaluation of the combination of cisplatin and its analogue carboplatin for platinum dose intensification in ovarian carcinoma. Cancer, 1993, 71, 3082-3090.	2.0	6
30	The DNA-binding epidermal growth factor-receptor inhibitor PD153035 and other DNA-intercalating cytotoxic drugs reactivate the expression of the retinoic acid receptor-Î² tumor-suppressor gene in breast cancer cells. Differentiation, 2007, 75, 883-890.	1.0	6
31	Long term storage in liquid nitrogen leads to only minor phenotypic and gene expression changes in the mammary carcinoma model cell line BT474. Oncotarget, 2017, 8, 35076-35087.	0.8	4
32	Ludwig Boltzmann Cluster Oncology (LBC ONC): first 10Âyears and future perspectives. Wiener Klinische Wochenschrift, 2018, 130, 517-529.	1.0	3
33	Increased lipid desaturation and ovarian cancer stem cells. Translational Cancer Research, 2017, 6, S472-S475.	0.4	2
34	Receptor signaling in cancer. Differentiation, 2007, 75, 767-769.	1.0	0
35	Abstract B01: Multilevel interference with receptor-PI3K-mTORC1 signaling is key mechanism for anticancer activity of fatty acid synthase inhibitors. , 2016, , .		0